• 1
    Kahaleh MB, LeRoy EC. Autoimmunity and vascular involvement in systemic sclerosis (SSc). Autoimmunity. 1999; 31: 195214.
  • 2
    Sgonc R, Gruschwitz MS, Dietrich H, et al. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest. 1996; 98: 78592.
  • 3
    Strange G, Nash P. The manifestations of vasculopathy in systemic sclerosis and its evidence-based therapy. Int J Rheum Dis. 2009; 12: 192206.
  • 4
    Miyazono K, Kamiya Y, Morikawa M. Bone morphogenetic protein receptors and signal transduction. J Biochem. 2010; 147: 3551.
  • 5
    Aldred MA, Vijayakrishnan J, James V, et al. BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Hum Mutat. 2006; 27: 2123.
    Direct Link:
  • 6
    Pietra GG, Capron F, Stewart S, et al. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol. 2004; 43: 25S32S.
  • 7
    Nasim MT, Ogo T, Chowdhury HM, et al. BMPR-II deficiency elicits pro-proliferative and anti-apoptotic responses through the activation of TGFbeta-TAK1-MAPK pathways in PAH. Hum Mol Genet. 2012; 21: 254858.
  • 8
    Atkinson C, Stewart S, Upton PD, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation. 2002; 105: 16728.
  • 9
    Morse J, Barst R, Horn E, et al. Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. J Rheumatol. 2002; 29: 237981.
  • 10
    Normand J, Karasek MA. A method for the isolation and serial propagation of keratinocytes, endothelial cells, and fibroblasts from a single punch biopsy of human skin. In Vitro Cell Dev Biol Anim. 1995; 31: 44755.
  • 11
    Qin W, Zhao B, Shi Y, et al. BMPRII is a direct target of miR-21. Acta Biochim Biophys Sin. 2009; 41: 61823.
  • 12
    Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum. 2006; 54: 22719.
  • 13
    Ding B, Kirkiles-Smith NC, Pober JS. FOXO3a regulates oxygen-responsive expression of tumor necrosis factor receptor 2 in human dermal microvascular endothelial cells. J Biol Chem. 2009; 284: 193319.
  • 14
    Tritz R, Mueller BM, Hickey MJ, et al. siRNA down-regulation of the PATZ1 gene in human glioma cells increases their sensitivity to apoptotic stimuli. Cancer Ther. 2008; 6: 86576.
  • 15
    Kypriotou M, Beauchef G, Chadjichristos C, et al. Human collagen Krox up-regulates type I collagen expression in normal and scleroderma fibroblasts through interaction with Sp1 and Sp3 transcription factors. J Biol Chem. 2007; 282: 3200014.
  • 16
    Czekierdowski A, Czekierdowska S, Danilos J, et al. Microvessel density and CpG island methylation of the THBS2 gene in malignant ovarian tumors. J Physiol Pharmacol. 2008; 59(Suppl. 4): 5365.
  • 17
    Zhu WG, Srinivasan K, Dai Z, et al. Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter. Mol Cell Biol. 2003; 23: 405665.
  • 18
    Gaddipati R, West J, Loyd J, et al. EGR1 is essential for transcriptional regulation of BMPR2. AJMB. 2011; 1: 1319.
  • 19
    Prescott RJ, Freemont AJ, Jones CJ, et al. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol. 1992; 166: 25563.
  • 20
    Fleischmajer R, Perlish JS. Capillary alterations in scleroderma. J Am Acad Dermatol. 1980; 2: 16170.
  • 21
    Harrison NK, Myers AR, Corrin B, et al. Structural features of interstitial lung disease in systemic sclerosis. Am Rev Respir Dis. 1991; 144: 70613.
  • 22
    de Caestecker M. The transforming growth factor-beta superfamily of receptors. Cytokine Growth Factor Rev. 2004; 15: 111.
  • 23
    Ehrlich M, Horbelt D, Marom B, et al. Homomeric and heteromeric complexes among TGF-beta and BMP receptors and their roles in signaling. Cell Signal. 2011; 23: 142432.
  • 24
    Teichert-Kuliszewska K, Kutryk MJ, Kuliszewski MA, et al. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension. Circ Res. 2006; 98: 20917.
  • 25
    Sugimori K, Matsui K, Motomura H, et al. BMP-2 prevents apoptosis of the N1511 chondrocytic cell line through PI3K/Akt-mediated NF-kappaB activation. J Bone Miner Metab. 2005; 23: 4119.
  • 26
    Liu Z, Shen J, Pu K, et al. GDF5 and BMP2 inhibit apoptosis via activation of BMPR2 and subsequent stabilization of XIAP. Biochim Biophys Acta. 2009; 1793: 181927.
  • 27
    Hong KH, Lee YJ, Lee E, et al. Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation. 2008; 118: 72230.
  • 28
    Star GP, Giovinazzo M, Langleben D. Effects of bone morphogenic proteins and transforming growth factor-beta on In-vitro production of endothelin-1 by human pulmonary microvascular endothelial cells. Vascul Pharmacol. 2009; 50: 4550.
  • 29
    Star GP, Giovinazzo M, Langleben D. ALK2 and BMPR2 knockdown and endothelin-1 production by pulmonary microvascular endothelial cells. Microvasc Res. 2013; 85: 4653.
  • 30
    David L, Feige JJ, Bailly S. Emerging role of bone morphogenetic proteins in angiogenesis. Cytokine Growth Factor Rev. 2009; 20: 20312.
  • 31
    de Jesus Perez VA, Alastalo TP, Wu JC, et al. Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-beta-catenin and Wnt-RhoA-Rac1 pathways. J Cell Biol. 2009; 184: 8399.
  • 32
    Abramowicz MJ, Van Haecke P, Demedts M, et al. Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation. Eur Respir J. 2003; 22: 5602.
  • 33
    Frank DB, Lowery J, Anderson L, et al. Increased susceptibility to hypoxic pulmonary hypertension in Bmpr2 mutant mice is associated with endothelial dysfunction in the pulmonary vasculature. Am J Physiol Lung Cell Mol Physiol. 2008; 294: L98109.
  • 34
    Herrick AL, Rieley F, Schofield D, et al. Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J Rheumatol. 1994; 21: 147783.
  • 35
    Sambo P, Baroni SS, Luchetti M, et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum. 2001; 44: 265364.
  • 36
    Andersen GN, Caidahl K, Kazzam E, et al. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis Rheum. 2000; 43: 108593.
  • 37
    Ogawa F, Shimizu K, Muroi E, et al. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis. Rheumatology. 2006; 45: 8158.
  • 38
    Svegliati S, Cancello R, Sambo P, et al. Platelet-derived growth factor and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS and Ras in systemic sclerosis fibroblasts. J Biol Chem. 2005; 280: 3647482.
  • 39
    Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. Cell. 2007; 128: 6358.
  • 40
    Schumacher A, Petronis A. Epigenetics of complex diseases: from general theory to laboratory experiments. Curr Top Microbiol Immunol. 2006; 310: 81115.
  • 41
    Bird A. Perceptions of epigenetics. Nature. 2007; 447: 3968.